Bitcoin broke through $90K resistance on January 3 after ETFs pulled in $471M on January 2. BTC now trades around $92K-$94K. A break above $95K could trigger a gamma squeeze toward $100K. Elevated ...

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in patients with advanced non-small cell lung cancer.

On Monday, AstraZeneca Plc (NASDAQ: AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab). The trial did not meet the primary endpoint of ...

The latest announcement is out from Insmed ( (INSM)). On December 17, 2025, Insmed announced the Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) did not ...

argenx SE retains a Hold rating due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART. Recent termination of TED and lupus nephritis programs narrows ...

A cancer-drug combination from Merck, Pfizer and Astellas Pharma has hit its goal in a second late-stage study in patients with a hard-to-treat form of bladder cancer. The companies on Wednesday said ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...

BMS and AstraZeneca said the IDMC does not believe the ACS trial will meet its primary endpoint. Image credit: Piyaset / Shutterstock.com. Bristol Myers Squibb (BMS) and AstraZeneca have decided to ...

Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...

On Tuesday, Merck & Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib). The trial met one ...

Edesa Biotech has shared data from its truncated phase 3 respiratory failure trial, linking the anti-TLR4 antibody to improvements in survival and recovery. The trial enrolled about 100 people who ...